The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...

TORONTO — Ontario is expanding access to six new cancer drugs through a pilot program designed to speed up public funding ...

The UCLA trial is currently enrolling patients.

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...

Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...

Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings ...